Barclays PLC Raises Stock Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

Barclays PLC grew its position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) by 248.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,308 shares of the company’s stock after buying an additional 5,925 shares during the quarter. Barclays PLC’s holdings in Contineum Therapeutics were worth $158,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sandia Investment Management LP bought a new stake in shares of Contineum Therapeutics in the second quarter valued at about $88,000. Rhumbline Advisers purchased a new position in Contineum Therapeutics during the 2nd quarter valued at about $118,000. BNP Paribas Financial Markets raised its holdings in shares of Contineum Therapeutics by 1,248.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock valued at $129,000 after purchasing an additional 6,243 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Contineum Therapeutics in the 2nd quarter worth approximately $356,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Contineum Therapeutics during the second quarter valued at approximately $1,174,000.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Baird R W raised shares of Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada reduced their price target on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird began coverage on Contineum Therapeutics in a research report on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $29.25.

Contineum Therapeutics Stock Down 3.2 %

NASDAQ CTNM opened at $13.77 on Wednesday. The firm’s fifty day simple moving average is $15.29 and its two-hundred day simple moving average is $17.48. Contineum Therapeutics, Inc. has a 12-month low of $12.33 and a 12-month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01. On average, analysts predict that Contineum Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Contineum Therapeutics Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).